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Hereditary Cancer Risk Assessment: New Perspectives and Challenges for the Next-Gen 
Sequencing Era
One of the greatest challenges in counseling families with cancer is conferring precise information 
regarding genetic susceptibilities, because it allows a better informed decision-making process about 
risk management, clinical surveillance, targeted-therapies, and preventive measures.
Genetic susceptibility to cancer can be driven by low-, intermediate-, or high-risk alleles in 
accordance to penetrance. Low-risk alleles comprise germline variants that are commonly shared 
among individuals, whose risks are near the risk of the general population, but, when many of them 
are inherited, they may increase risk substantially. For susceptible carriers, evidence-based guidelines 
do not yet exist for cancer screening. Intermediate-risk alleles have a moderate penetrance, although 
there are limited data on the degree of cancer risk, because they may be influenced by gene–gene 
or gene–environment interactions. For the carriers of these variants, there are no clear guidelines 
on risk management, and in many cases, the information from testing does not modify clinical 
management compared to that based on family history alone. Finally, the high-risk alleles are those 
that cause familial cancer syndromes with high penetrance. For these deleterious variants, genetic 
counseling and clinical management provide the greatest benefits, but, simultaneously, uncover the 
greatest challenges in terms of psychosocial and ethical issues.
One such familial cancer syndrome is Li–Fraumeni, which arises from germline mutations in 
TP53. This syndrome has been extensively studied in the Brazilian population, where a founder 
mutation is present (1). Nogueira et al. described the use of 18F-FDG-PET/CT for cancer detection 
in asymptomatic TP53 mutation carriers. Twenty percent of patients showed lesions, supporting the 
clinical utility of PET/CT in addition to other imaging procedures for screening (Nogueira et al.).
Regarding psychosocial problems with genetic testing, Quinlivan et al. analyzed the attitudes of 
recent mothers toward a fictitious test for genes conferring a 50% risk of cancer. Only one-third of 
participants indicated that would have undergone the genetic test. The decision to test was correlated 
with previous acceptance of a Down syndrome screening in pregnancy, and with lack of worries 
about emotional, employment, and insurance discrimination (Quinlivan et al.). A fear of discrimina-
tion is among the biggest problems in the decision-making process.
The American College of Medical Genetics and Genomics (ACMG) has recommended analysis of 
56 specific genes when reporting incidental or secondary findings from next-generation sequencing 
(NGS) technologies (2). Germline mutations in 16 of these genes cause hereditary cancer syndromes. 
The ACMG later updated its recommendations, based on the general consensus that patients should 
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be able to opt out of the analysis of secondary findings, during 
the pre-test counseling sessions. Some of these cancer syndromes 
may have pretty early onset, so these guidelines are also applied 
to children, whose parents shall have to make the decision of 
opting out or not (3). An elegant recent review by Kuhlen and 
Borkhardt shows that following the recommendations of national 
and international human genetic societies and the legislation of 
most European countries, children and their parents must be 
previously and thoroughly informed about which findings should 
be reported through a written consent. The ordering physician is 
obliged to discuss with the child and/or parents all the possibili-
ties of results, including the disclosure of incidental findings, the 
“right not to know,” the benefits and risks, as well is who has the 
responsibility for obtaining the informed consent and providing 
pre- and post-test counseling (4).
The clinical utility and validity of using NGS for hereditary 
cancer risk assessment are becoming a reality in cancer genetics 
clinics. One advantage of NGS is the feasibility of including 
multiple genes in panels tailored to a certain familial aggrega-
tion of tumors, such as breast or colon cancer. Nevertheless, 
because of its economic viability, whole-exome/genome 
sequencing has displaced the phenotype-driven hypothesis 
approach that is based on the characteristics and genotype–
phenotype correlations of the syndrome. Slavin et  al. showed 
interesting results about multigene panels in a reference cancer 
genetics clinic. When panels included only high-risk genes, the 
results were seldom positive, and more variants of unknown 
significance (VUS) were revealed. This result is likely because of 
the inclusion of more genes in these so-called “off-phenotype” 
pan-cancer panels (Slavin et al.). Compared to single-gene tests, 
cancer panels are time- and cost-efficient in cases with (1) sub-
stantial genetic or locus heterogeneity, (2) high prevalence of 
actionable mutations in one of several genes, (3) difficulty in 
predicting the mutated gene based on phenotype or family his-
tory alone, or (4) non-informative or unavailable family history 
(e.g., adoption) (5). Recent evidence-based guidelines, such as 
those of the National Comprehensive Cancer Network, have 
included the use of multigene testing for familial breast and 
ovarian cancer risk assessment, comparing its advantages and 
disadvantages (6).
A critical disadvantage of NGS is the possibility of disclos-
ing inconclusive or uncertain results. Identification of a VUS 
hampers the interpretation of phenotype and genotype data, 
rendering genetic counseling a stressful task. As Slavin et  al. 
stated, choosing a phenotype-specific panel with genes of high 
clinical utility instead of pan-cancer panels with many low-risk 
genes can decrease the chance of finding variants that are difficult 
to interpret (Slavin et al.). Pinheiro et al. discussed these issues, 
offering contrasting arguments. They showed that there is now 
a tendency for relaxing clinical criteria to select for genetic test-
ing those individuals in a family with the highest risk of cancer, 
such as individuals with a very early age of onset with no affected 
relatives. A specific syndrome and specific gene would no longer 
need to be targeted for testing if a multigene panel were available. 
However, the value of a strategy with less stringent criteria may 
be debatable because of the costs of screening, as more individu-
als would become eligible for testing, despite the costs of NGS 
continuing to decline (Pinheiro et al.).
Therefore, there must be a rationale to offer the proper genetic 
test to a family member with cancer. There is an urgent need for 
implementing multidisciplinary teams, led by a cancer geneticist, 
in reference settings. Such teams will provide patients and their 
relatives with the best-informed decision-making process and 
risk assessment, as we balance the breakthroughs and challenges 
of the NGS era.
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